New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 3, 2013
08:00 EDTAMGN, AMGN, SNY, SNY, GENZ, GENZ, TEVA, TEVAFDA to hold a joint committee meeting
Joint Meeting of the Medical Imaging Drugs Advisory Committee and Oncologic Drugs Advisory Committee is being held to discuss the safety and efficacy of currently approved leukocyte growth factors (LGFs) as potential treatments for radiation-induced myelosuppression associated with a radiological/nuclear incident. The meeting will be held at FDA Silver Spring, Maryland offices on May 3 at 8 am. Webcast Link
News For AMGN;SNY;GENZ;TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
August 25, 2015
17:11 EDTTEVAU.S. District Court rules in Eli Lilly's favor on Alimta vitamin regimen patent
Subscribe for More Information
15:02 EDTTEVAMylan says USPTO institutes IPR of two Copaxone patents
Subscribe for More Information
14:40 EDTTEVATeva Copaxone patents to be reconsidered by regulators, Bloomberg says
11:27 EDTTEVATeva to refrain from voting at Mylan special meeting
Subscribe for More Information
09:16 EDTAMGNAmgen to present Repatha data analysis at ESC Congress 2015
Subscribe for More Information
09:02 EDTAMGNAmgen submits NDA for hyperparathyroidism treatment
Subscribe for More Information
08:17 EDTTEVATeva multiple low, says Leerink
Subscribe for More Information
August 24, 2015
13:36 EDTAMGNBiotech correction presents some opportunities, says RBC Capital
RBC Capital analyst Michael Yee said he won't try to pick the short-term bottom in biotech, but contends that any macro weakness in China shouldn't have any major impact to financials or fundamentals for the sector given their minimal exposure there. If the market continues to be volatile, Yee recommends a focus on names with defensive characteristics, such as higher margins and free cash flow yield, naming Amgen (AMGN), Celgene (CELG) and Gilead (GILD) as some examples. The analyst adds that he likes Vertex (VRTX) on the pullback for "more aggressive" growth investors. Yee has Outperform ratings on all of the stocks mentioned above.
10:20 EDTTEVATeva says EMA confirms validation of reslizumab MAA
Subscribe for More Information
August 21, 2015
05:51 EDTTEVAStocks with implied volatility below IV index mean; GMCR TEVA
Stocks with implied volatility below IV index mean; Teva (TEVA) 25, Keurig Green Mountain (GMCR) 39 according to iVolatility.
August 20, 2015
11:33 EDTSNYLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
05:58 EDTTEVAStocks with implied volatility below IV index mean; GMCR TEVA
Stocks with implied volatility below IV index mean; Teva (TEVA) 23, Keurig Green Mountain (GMCR) 37 according to iVolatility.
05:57 EDTTEVAStocks with implied volatility below IV index mean; GMCR TEVA
Subscribe for More Information
August 18, 2015
12:06 EDTAMGNAmgen to pay $71M in 48-state settlement over Aranesp, Enbrel promotions
West Virginia Attorney General Patrick Morrisey announced his Office has participated in a $71M multi-state settlement with Amgen to resolve allegations it unlawfully promoted the biologic medications Aranesp and Enbrel. West Virginia will receive $845,637.82 as part of the settlement, which was negotiated between the company and Attorneys General from 48 states and the District of Columbia. A complaint in the matter was filed Tuesday morning in Kanawha County Circuit Court. Aranesp is used to treat certain types of anemia by stimulating bone marrow to produce red blood cells. Enbrel is used to treat a number of conditions, including plaque psoriasis. In addition to the $71M settlement, the agreement requires Amgen to reform its marketing and promotional practices. In addition to West Virginia, the other states participating in this settlement are Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, Wisconsin and Wyoming and the District of Columbia.
09:19 EDTAMGNPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
09:07 EDTAMGNAmgen and University of California announce education program partnership
Amgen and the Center for Social Sector Leadership at the University of California, or UC, Berkeley's Haas School of Business announced a multi-year partnership to offer a graduate-level course on measuring outcomes of cancer patient advocacy education and support programs. The MBA course, Social Impact Metrics, is designed to advance the ability of nonprofit organizations to measure the effectiveness of their programs, which is critical in an increasingly challenging donor environment. The overall goal of the initiative is to create a set of measurement best practices that can be adopted across the cancer nonprofit community and beyond.
08:04 EDTTEVATeva shares reflect Copaxone franchise risk, says Morgan Stanley
Subscribe for More Information
August 17, 2015
08:23 EDTAMGNDeutsche Bank biotech analyst holds an analyst/industry conference call
Subscribe for More Information
August 14, 2015
17:08 EDTTEVAPaulson & Co gives quarterly update on stakes
Subscribe for More Information
16:44 EDTAMGNThird Point gives quarterly update on stakes
NEW STAKES: Baxter (BAX), T-Mobile (TMUS), Sealed Air (SEE), Devon (DVN), and Perrigo (PRGO). INCREASED STAKES: SunEdison (SUNE), Dow Chemical (DOW), Mohawk (MHK), Yum! Brands (YUM), and IAC/InterActiveCorp (IACI). DECREASED STAKES: Ally Financial (ALLY), Amgen (AMGN), Sensata (ST), Masco (MAS), and Delta (DAL). LIQUIDATED STAKES: Dollar General (DG), McKesson (MCK), Edgewell Personal Care (EPC), Maxim (MXIM), and FleetCor (FLT).
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use